Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

427
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
427
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.3K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.3K
Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

124
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
124
Glaucoma: Overview01:25

Glaucoma: Overview

796
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
796
Trachea01:22

Trachea

2.8K
The trachea, commonly known as the windpipe, is a vital part of the human respiratory system. It serves as a passageway for air to travel between the larynx and the bronchi, allowing oxygen to reach the lungs. Let's explore its anatomical features, dimensions, layers of the tracheal wall, associated muscles, and the functions of its parts.
Anatomical Features:
Location: About half of the trachea is situated in the neck, anterior to the esophagus, and extends from the larynx (at the level of...
2.8K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

728
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
728

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A snapshot of selected neglected tropical disease research using the World Health Organization International Clinical Trials Registry Platform database, 1999-2023.

PLoS neglected tropical diseases·2026
Same author

Advancing health-care access to optimise health and quality of life for children and young people with Down syndrome worldwide.

The Lancet. Child & adolescent health·2026
Same author

Strengthening health-care pathways for people with Down syndrome.

The lancet. Healthy longevity·2026
Same author

Challenges, barriers and opportunities for neglected tropical disease programs of conflict-affected African countries.

International health·2026
Same author

Neglected tropical diseases in conflict-related humanitarian emergency settings: a systematic review of the literature.

International health·2026
Same author

Evaluation of a face-washing behaviour change intervention for trachoma prevention in Oromia, Ethiopia (Stronger SAFE): secondary outcomes of a cluster-randomised controlled trial.

The Lancet. Global health·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Sep 20, 2025

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections
09:11

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections

Published on: August 11, 2012

13.1K

トラコーマ

Esmael Habtamu1, Emma M Harding-Esch2, Katie Greenland3

  • 1Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK; Eyu-Ethiopia, Bahir Dar, Ethiopia; Department of Ophthalmology, College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia.

Lancet (London, England)
|May 24, 2025
PubMed
まとめ
この要約は機械生成です。

トラコーマは 感染症による失明の 主な原因で 2030年までに 全球的に撲滅するための 継続的な取り組みが必要です 世界保健機関 (WHO) の目標を達成するために,新しい戦略が必要です.

さらに関連する動画

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.0K
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
07:30

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction

Published on: October 13, 2017

11.2K

関連する実験動画

Last Updated: Sep 20, 2025

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections
09:11

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections

Published on: August 11, 2012

13.1K
Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.0K
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
07:30

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction

Published on: October 13, 2017

11.2K

科学分野:

  • 眼科について
  • 感染症
  • 公衆衛生

背景:

  • トラコーマは 感染症による失明の主要な原因であり,世界保健機関の2030年の 撲滅目標の主要な焦点です.
  • 結膜の痕と潜在的に不可逆的な視力喪失につながる. 結膜の痕と潜在的に不可逆的な視力喪失を引き起こす.
  • 影響を受ける人々は 貧しい農村部に住んでいて 水道や衛生施設へのアクセスが 限られていることが多いので 女性や子供に不釣り合いな影響を及ぼします

研究 の 目的:

  • 公共衛生問題としてのトラコーマの撲滅における世界的な進展と課題をレビューする.
  • SAFE戦略の有効性を強調する (手術,抗生物質,顔の清潔さ,環境改善).
  • 持続的で再発するトラコーマと闘うための新しい方法や強化方法の必要性を特定する.

主な方法:

  • この研究は,世界中のトラコーマ除去プログラムの現状を レビューしたものです.
  • この報告書は,過去20年間にわたってSAFE戦略がもたらした影響と成功を分析しています.
  • 持続的または再発性アクティブなトラコーマの領域を特定します.

主要な成果:

  • SAFE戦略はかなりの成功を収め,2024年12月までに21カ国がトラコーマを撲滅しました.
  • 他にも多くの国が 絶滅の目標を達成する道を歩んでいます
  • しかし,特定の集団における持続的および再発性アクティブトラコーマにより,課題は残っています.

結論:

  • 2030年のトラコーマ撲滅の目標には大きな進展がみられたが,課題は依然として残っている.
  • 継続的な成功には,新しい介入や強化された介入の開発と実施が必要です.
  • 慢性的な病気の環境では 駆除の努力を加速することが重要です